Related Experiment Video
Updated: Mar 14, 2026
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective
1Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo hhorinou@ncc.go.jp.
Abstract:
A number of promising new approaches for both local and systemic control of locally advanced non-small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from advanced non-small cell lung cancer is mandatory. As for radiotherapy, adaptive radiotherapy and proton therapy are under investigation after the RTOG 0617 trial unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III disease. To date, no Phase III trial has clearly shown the benefit of adding surgery as a part of multimodality therapy for locally advanced non-small cell lung cancer. Such poor progress in the development of effective treatments for Stage III non-small cell lung cancer is considered to be attributable to the existence of heterogeneities in the disease characteristics, including the biological and anatomic characteristics. Constant effort via well-designed and well-conducted clinical trials is needed to decipher the heterogeneity of Stage III non-small cell lung cancer.
Insights
New treatments for locally advanced non-small cell lung cancer are being explored. Overcoming disease heterogeneity through rigorous clinical trials is crucial for improving patient survival in Stage III lung cancer.
Area of Science:
- Oncology
- Medical Physics
Background:
- Locally advanced non-small cell lung cancer (NSCLC) treatment requires improved systemic therapies and radiotherapy approaches.
- Current treatment strategies face challenges due to disease heterogeneity.
Purpose of the Study:
- To review promising new therapeutic strategies for locally advanced non-small cell lung cancer.
- To highlight the need for further research into overcoming treatment resistance and heterogeneity.
Main Methods:
- Review of clinical trials investigating novel systemic agents (EGFR-TKIs, ICIs) and radiotherapy techniques (adaptive, proton).
- Analysis of outcomes from trials like RTOG 0617 and the lack of Phase III evidence for surgery in multimodality treatment.
Main Results:
- New systemic agents show promise, but radiotherapy efficacy needs further validation.
- No Phase III trial has definitively proven the benefit of adding surgery to multimodality therapy for locally advanced NSCLC.
Conclusions:
- Advancements in systemic therapies and radiotherapy are under investigation for locally advanced NSCLC.
- Understanding and addressing the biological and anatomical heterogeneities of Stage III NSCLC is essential for therapeutic progress.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy